<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00844298</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000632225</org_study_id>
    <secondary_id>AMC-UUCM-2008-0310</secondary_id>
    <secondary_id>NOVARTIS-AMC-UUCM-2008-0310</secondary_id>
    <nct_id>NCT00844298</nct_id>
  </id_info>
  <brief_title>Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Tasigna® (Nilotinib) Plus Multi-Agent Chemotherapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Nilotinib may stop the growth of cancer cells by blocking some of the enzymes
      needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth
      of cancer cells, either by killing the cells or by stopping them from dividing. Giving
      nilotinib together with combination chemotherapy may kill more cancer cells.

      PURPOSE: This phase II trial is studying how well giving nilotinib together with combination
      chemotherapy works in treating patients with newly diagnosed acute lymphoblastic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the clinical efficacy of nilotinib and combination chemotherapy, in terms
           of hematologic and molecular complete remission (CR) rates, in patients with newly
           diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia or acute mixed
           lineage leukemia.

      Secondary

        -  To establish the prognostic factors for patients treated with this regimen.

        -  To determine the duration of CR in patients treated with this regimen.

        -  To determine the duration of progression-free and overall survival of these patients.

        -  To determine the toxicity of this regimen in these patients.

      OUTLINE: This is a multicenter study. Patients are stratified according to age (15 to 64
      years vs ≥ 65 years).

        -  Induction therapy: Patients receive daunorubicin hydrochloride IV continuously over 24
           hours on days 1-3, vincristine sulfate IV on days 1 and 8, and oral prednisolone on days
           1-14. Patients undergo bone marrow examination on day 14. Patients in hematologic
           remission proceed to consolidation therapy. Patients with residual leukemic cells &gt; 5%
           receive an additional dose of daunorubicin hydrochloride IV continuously over 24 hours
           on day 15 before proceeding to consolidation therapy.

        -  Consolidation therapy: For course 1, patients receive daunorubicin hydrochloride IV
           continuously over 24 hours on days 1 and 2, vincristine sulfate IV on days 1 and 8, and
           oral prednisolone on days 1-14. For courses 2 and 4, patients receive cytarabine IV over
           2 hours and etoposide IV over 3 hours on days 1-4. For courses 3 and 5, patients receive
           methotrexate IV continuously over 36 hours on days 1, 2, 15, and 16 and leucovorin
           calcium IV every 6 hours for 3 doses and then orally until blood methotrexate levels are
           in a safe range.

      Patients also receive oral nilotinib twice daily beginning on day 8 of induction therapy and
      continuing until the completion of consolidation therapy.

      After completion of consolidation therapy, patients with a hematopoietic stem cell donor
      proceed to allogeneic hematopoietic stem cell transplantation (HSCT). Patients who do not
      undergo HSCT continue to receive oral nilotinib twice daily for up to 2 years after
      completion of consolidation therapy.

      After completion of study therapy, patients are followed periodically for up to 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Achieving Hematologic and Molecular Complete Remission (CR) After Induction Therapy</measure>
    <time_frame>1 month</time_frame>
    <description>approximate time: at the recovery of cytopenia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease(Relapse)-Free Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Nilotinib+mVPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who were Philadelphia-positive, newly-diagnosed adult ALL and treated with nilotinib + mVPD treatment plan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib+mVPD</intervention_name>
    <description>Induction:
Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)
Vincristine 2 mg iv push (d1, 8, 15, 22)
Prednisolone 60 mg/m2/day po (d1-28)
Nilotinib 400mg bid/d (d8-)
Consolidation A (cycle1)
Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)
Vincristine 2 mg iv (d1, 8)
Prednisolone 60 mg/m2/day po (d1-14)
Nilotinib 400mg bid/d
Consolidation B (cycles 2&amp;4)
Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)
Etoposide 150 mg/m2/day iv over 3 hours (d1-4)
Nilotinib 400mg bid/d
Consolidation C (cycles 3&amp;5)
Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)
Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,
Nilotinib 400mg bid/d
Maintenance
◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)
Consider alloHCT</description>
    <arm_group_label>Nilotinib+mVPD</arm_group_label>
    <other_name>Mabthera</other_name>
    <other_name>VCS</other_name>
    <other_name>Daunobrastina</other_name>
    <other_name>Solondo</other_name>
    <other_name>Leunase</other_name>
    <other_name>Cytarabine</other_name>
    <other_name>Efosin</other_name>
    <other_name>DBLMethotrexate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Newly diagnosed acute lymphoblastic leukemia or acute mixed lineage leukemia

               -  Positive for Bcr-Abl fusion transcript (Philadelphia chromosome-positive disease)
                  by RT-PCR

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Total bilirubin &lt; 2 mg/dL

          -  SGOT &lt; 3 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 2.5 times ULN (unless considered tumor-related)

          -  Creatinine &lt; 2.0 mg/dL ULN

          -  Serum amylase and lipase ≤ 1.5 times ULN

          -  Potassium, magnesium, and phosphorus normal (supplementation allowed)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No rare hereditary problems with galactose intolerance, severe lactase deficiency, or
             glucose-galactose malabsorption

          -  No known sensitivity to any of the study drugs

          -  No severe medical condition that, in the opinion of the investigator, would preclude
             study participation

          -  No impaired cardiac function, including any of the following:

               -  LVEF &lt; 45% or below the lower limit of normal by ECHO

               -  Long QT syndrome or known family history of long QT syndrome

               -  Clinically significant resting bradycardia (&lt; 50 beats per minute)

               -  QTc &gt; 450 msec on baseline ECG (using the QTcF formula)

               -  Myocardial infarction within the past 12 months

               -  Other clinically significant heart disease, including any of the following:

                    -  Unstable angina

                    -  Congestive heart failure

                    -  Uncontrolled hypertension

                    -  Uncontrolled arrhythmias

          -  No other primary malignant disease requiring systemic treatment

          -  No acute or chronic liver, pancreatic, or severe renal disease

          -  No other severe and/or life-threatening medical disease

          -  No history of significant congenital or acquired bleeding disorder unrelated to cancer

          -  No impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of study drug

          -  No history of non-compliance

        PRIOR CONCURRENT THERAPY:

          -  More than 30 days since prior investigational agents

          -  No concurrent medications that have the potential to prolong the QTc interval

          -  No concurrent strong CYP3A4 inhibitors

          -  No concurrent therapeutic coumarin derivatives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoo H. Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Daegu Fatima Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>701-600</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>702-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>712-749</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center - Korea</name>
      <address>
        <city>Goyang</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Jeollanam-do</city>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Jinju</city>
        <zip>660-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Seoul Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>100-032</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center - University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>441-749</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2009</study_first_submitted>
  <study_first_submitted_qc>February 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2009</study_first_posted>
  <results_first_submitted>August 7, 2015</results_first_submitted>
  <results_first_submitted_qc>August 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2015</results_first_posted>
  <last_update_submitted>August 7, 2015</last_update_submitted>
  <last_update_submitted_qc>August 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Kyoo-Hyung Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nilotinib+mVPD</title>
          <description>Patients who were Philadelphia-positive, newly-diagnosed adult ALL and treated with nilotinib + mVPD treatment plan
Nilotinib+mVPD: 1.Induction:
Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)
Vincristine 2 mg iv push (d1, 8, 15, 22)
Prednisolone 60 mg/m2/day po (d1-28)
Nilotinib 400mg bid/d (d8-) 2.Consolidation A (cycle1)
Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)
Vincristine 2 mg iv (d1, 8)
Prednisolone 60 mg/m2/day po (d1-14)
Nilotinib 400mg bid/d
3. Consolidation B (cycles 2&amp;4)
Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)
Etoposide 150 mg/m2/day iv over 3 hours (d1-4)
Nilotinib 400mg bid/d
4.Consolidation C (cycles 3&amp;5)
Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)
Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,
Nilotinib 400mg bid/d
5.Maintenance
Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)
6.Consider alloHCT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nilotinib+mVPD</title>
          <description>Patients who were Philadelphia-positive, newly-diagnosed adult ALL and treated with nilotinib + mVPD treatment plan
Nilotinib+mVPD: 1.Induction:
Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)
Vincristine 2 mg iv push (d1, 8, 15, 22)
Prednisolone 60 mg/m2/day po (d1-28)
Nilotinib 400mg bid/d (d8-) 2.Consolidation A (cycle1)
Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)
Vincristine 2 mg iv (d1, 8)
Prednisolone 60 mg/m2/day po (d1-14)
Nilotinib 400mg bid/d
3. Consolidation B (cycles 2&amp;4)
Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)
Etoposide 150 mg/m2/day iv over 3 hours (d1-4)
Nilotinib 400mg bid/d
4.Consolidation C (cycles 3&amp;5)
Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)
Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,
Nilotinib 400mg bid/d
5.Maintenance
Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)
6.Consider alloHCT</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.0" lower_limit="17" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Achieving Hematologic and Molecular Complete Remission (CR) After Induction Therapy</title>
        <description>approximate time: at the recovery of cytopenia</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib+mVPD</title>
            <description>Patients who were Philadelphia-positive, newly-diagnosed adult ALL and treated with nilotinib + mVPD treatment plan
Nilotinib+mVPD: 1.Induction:
Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)
Vincristine 2 mg iv push (d1, 8, 15, 22)
Prednisolone 60 mg/m2/day po (d1-28)
Nilotinib 400mg bid/d (d8-) 2.Consolidation A (cycle1)
Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)
Vincristine 2 mg iv (d1, 8)
Prednisolone 60 mg/m2/day po (d1-14)
Nilotinib 400mg bid/d
3. Consolidation B (cycles 2&amp;4)
Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)
Etoposide 150 mg/m2/day iv over 3 hours (d1-4)
Nilotinib 400mg bid/d
4.Consolidation C (cycles 3&amp;5)
Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)
Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,
Nilotinib 400mg bid/d
5.Maintenance
Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)
6.Consider alloHCT</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Achieving Hematologic and Molecular Complete Remission (CR) After Induction Therapy</title>
          <description>approximate time: at the recovery of cytopenia</description>
          <units>percentage of analyzable subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease(Relapse)-Free Survival</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nilotinib+mVPD</title>
          <description>Patients who were Philadelphia-positive, newly-diagnosed adult ALL and treated with nilotinib + mVPD treatment plan
Nilotinib+mVPD: 1.Induction:
Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)
Vincristine 2 mg iv push (d1, 8, 15, 22)
Prednisolone 60 mg/m2/day po (d1-28)
Nilotinib 400mg bid/d (d8-) 2.Consolidation A (cycle1)
Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)
Vincristine 2 mg iv (d1, 8)
Prednisolone 60 mg/m2/day po (d1-14)
Nilotinib 400mg bid/d
3. Consolidation B (cycles 2&amp;4)
Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)
Etoposide 150 mg/m2/day iv over 3 hours (d1-4)
Nilotinib 400mg bid/d
4.Consolidation C (cycles 3&amp;5)
Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)
Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,
Nilotinib 400mg bid/d
5.Maintenance
Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)
6.Consider alloHCT</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="214" subjects_affected="79" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitation of the current study was that this study was not performed in a randomized comparative way, and the advantages of nilotinib over other TKIs were not definitely demonstrated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Dae-Young Kim</name_or_title>
      <organization>Asan Medical Center, University of Ulsan College of Medicine</organization>
      <phone>82230105930</phone>
      <email>dani@amc.seoul.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

